ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
Open access · hybridAbstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 4 pooled it
52.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 4 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- [Hereditary genetic testing and its application in the diagnosis, treatment, and prevention of breast cancer].Magyar onkologia · 2025Guideline
- ARTEMIS: An independently validated prognostic prediction model of breast cancer incorporating epigenetic biomarkers with main effects and gene-gene interactions.Journal of advanced research · 2025Pooled it
- Secondary Risk-Reducing Strategies for Contralateral Breast Cancer in BRCA1/2 Variant Carriers: A Systematic Review and Meta-analysis.Advances in therapy · 2025Pooled it
- Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Genetics in medicine : official journal of the American College of Medical Genetics · 2023Guideline
- Identifying Mediators of Intervention Effects Within a Randomized Controlled Trial to Motivate Cancer Genetic Risk Assessment Among Breast and Ovarian Cancer Survivors.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2023Trial
- A Randomized Trial Comparing the Effectiveness of Pre-test Genetic Counseling Using an Artificial Intelligence Automated Chatbot and Traditional In-person Genetic Counseling in Women Newly Diagnosed with Breast Cancer.Annals of surgical oncology · 2023Trial
- Potential advantage of clinical exome sequencing inJournal of medical genetics · 2026Article
- Factors influencing decision regret regarding contralateral prophylactic mastectomy in women at high risk of hereditary breast cancer: a cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Surgical Management of Early-Onset Breast Cancer Among Young BRCA1 and BRCA2 Carriers.JAMA network open · 2026Article
- GermlineGenes · 2026Article
- Inverse GAS5-SFXN1 Correlation in Triple-Negative Breast Cancer: Insights from Bioinformatics and Tissue Expression Analysis.Iranian biomedical journal · 2026Article
- Integrating multi-omics and clinical management in breast cancer: a comprehensive review.Discover oncology · 2026Review
- Are current Polish guidelines for prophylactic mastectomy sufficient?Hereditary cancer in clinical practice · 2026Review
- Contralateral breast cancer risks for BRCA1, BRCA2, PALB2, CHEK2, and ATM pathogenic variant carriers in two large cohort studies.BJC reports · 2026Article
- Analysis of low-benefit subgroups in breast-conserving surgery: Implications for clinical decision-making (Review).Experimental and therapeutic medicine · 2026Review
- Barriers and facilitators for online genetic care for hereditary cancer in Japan: findings from surveys of both clients and medical professionals.International journal of clinical oncology · 2026Article
- Article
- Remarkable response of metaplastic breast cancer to a novel targeted AKT inhibitor TAS-117 in a Cowden syndrome patient: a case report.BJC reports · 2026Article
- Risk of Radiation-Associated Contralateral Breast Cancer in Germline Mutation Carriers: A Meta-Analysis and Systematic Review.Cancers · 2026Review
- Age-related genomic characterization and therapeutic targets in Chinese breast cancer: insights from prospective targeted sequencing and clinical data analysis.BMC medicine · 2026Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 15 institutions in 1 country.
Siddhartha YadavDepartment of Oncology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-4630-9903
Nicholas J BoddickerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.ORCID 0000-0002-6784-2072
Jie NaDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.ORCID 0000-0003-3435-1805
Eric C PolleyDepartment of Public Health Sciences, University of Chicago, Chicago, IL.ORCID 0000-0002-5152-8740
Chunling HuDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-6814-4639
Steven N HartDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.ORCID 0000-0001-7714-2734
Rohan D GnanaolivuDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
Nicole LarsonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.ORCID 0000-0002-2129-6934
Susan HoltegaardDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Huaizhi HuangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.
Carolyn A DunnDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Lauren R TerasDepartment of Population Science, American Cancer Society, Atlanta, GA.ORCID 0000-0003-2419-8536
Alpa V PatelDepartment of Population Science, American Cancer Society, Atlanta, GA.
James V LaceyBeckman Research Institute of City of Hope, Duarte, CA.
Susan L NeuhausenBeckman Research Institute of City of Hope, Duarte, CA.ORCID 0000-0001-5053-0390
Elena MartinezDepartment of Family Medicine and Public Health, University of California, San Diego, CA.ORCID 0000-0002-6728-1834
Christopher HaimanKeck School of Medicine, University of Southern California, Los Angeles, CA.ORCID 0000-0002-0097-9971
Fei ChenKeck School of Medicine, University of Southern California, Los Angeles, CA.ORCID 0000-0002-1679-9932
Kathryn J RuddyDepartment of Oncology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-6298-332X
Janet E OlsonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
Esther M JohnDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0003-3259-8003
Allison W KurianDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0002-6175-9470
Dale P SandlerNational Institute of Environmental Health Sciences, Durham, NC.ORCID 0000-0002-6776-0018
Katie M O'BrienNational Institute of Environmental Health Sciences, Durham, NC.ORCID 0000-0002-1931-1349
Jack A TaylorNational Institute of Environmental Health Sciences, Durham, NC.ORCID 0000-0001-5303-6398
Clarice R WeinbergNational Institute of Environmental Health Sciences, Durham, NC.
Hoda Anton-CulverUniversity of California, Irvine, CA.ORCID 0000-0002-9603-0110
Argyrios ZiogasUniversity of California, Irvine, CA.ORCID 0000-0003-4529-3727
Gary ZirpoliSlone Epidemiology Center at Boston University, Boston, MA.ORCID 0000-0003-1417-5349
David E GoldgarUniversity of Utah, Salt Lake City, UT.ORCID 0000-0003-0697-9347
Julie R PalmerSlone Epidemiology Center at Boston University, Boston, MA.ORCID 0000-0002-6534-335X
Susan M DomchekDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-5914-7272
Jeffrey N WeitzelLatin American School of Oncology, Sierra Madre, CA.ORCID 0000-0001-6714-092X
Katherine L NathansonDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-6740-0901
Peter KraftHarvard University T.H. Chan School of Public Health, Boston, MA.ORCID 0000-0002-4472-8103
Fergus J CouchDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-9417-9985
Mayo Clinic in Arizona · USMayo Clinic in Florida · USNational Institute of Environmental Health Sciences · USAmerican Cancer Society · USBoston University · USCity of Hope · USStanford University · USUniversity of California, Irvine · USUniversity of Pennsylvania · USUniversity of Southern California · USChicago Department of Public Health · USHarvard University · USMayo Clinic · USUniversity of California San Diego · USUniversity of Utah · US
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MThe Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2005 to 2026
$49.9MUnderstanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4MA Follow-up Study for Causes of Cancer in Black WomenU01CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Kimberly A. Bertrand, Yvette C Cozier · 2017 to 2026
$24.0MEnvironmental and Genetic Risk Factors For Breast Cancer: The Sister StudyZIAES044005 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI SANDLER, DALE P · 2009 to 2025
$22.7MPaul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · NCI · MAYO CLINIC ROCHESTER · PI WEROHA, SARAVUT · 2001 to 2025
$19.7MUnderstanding Ethnic Differences in Cancer: The Multiethnic Cohort StudyUM1CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HENDERSON, BRIAN E, LE MARCHAND, LOIC · 2012 to 2014
$11.3MThe Two Sister StudyZIAES102245 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI WEINBERG, CLARICE · 2009 to 2025
$8.6MRisk and penetrance of mutations from breast cancer testing panels.R01CA192393 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH, NATHANSON, KATHERINE L. · 2014 to 2018
$6.3MResolving the cancer relevance of predisposition gene mutationsR35CA253187 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2020 to 2026
$5.8MThe contribution of RAD51C and RAD51D to breast and ovarian cancerR01CA225662 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH, WEROHA, SARAVUT · 2018 to 2024
$2.5MHEREDITARY BREAST CANCER--GENETIC AND MOLECULAR STUDIESU01CA058860 · NCI · UNIVERSITY OF CALIFORNIA IRVINE · PI ANTON-CULVER, HODA A. · 1997 to 2002
$2.5MIntramural NIH HHS Z01 ES044005Intramural NIH HHS Z01 ES049033Intramural NIH HHS ZIA ES102245NCI NIH HHS K12 CA090628NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA192393NCI NIH HHS R01 CA225662NCI NIH HHS R35 CA253187NCI NIH HHS T32 CA229110NCI NIH HHS U01 CA058860NCI NIH HHS U01 CA164973NCI NIH HHS U01 CA164974NCI NIH HHS UM1 CA164973
Abstract
purposeTo estimate the risk of contralateral breast cancer (CBC) among women with germline pathogenic variants (PVs) in
methodsThe study population included 15,104 prospectively followed women within the CARRIERS study treated with ipsilateral surgery for invasive breast cancer. The risk of CBC was estimated for PV carriers in each gene compared with women without PVs in a multivariate proportional hazard regression analysis accounting for the competing risk of death and adjusting for patient and tumor characteristics. The primary analyses focused on the overall cohort and on women from the general population. Secondary analyses examined associations by race/ethnicity, age at primary breast cancer diagnosis, menopausal status, and tumor estrogen receptor (ER) status.
resultsGermline
conclusionWomen diagnosed with breast cancer and known to carry germline PVs in
Indexed as
Breast NeoplasmsGenetic Predisposition to DiseaseAtaxia Telangiectasia Mutated ProteinsBlack or African AmericanBRCA1 ProteinBRCA2 ProteinCheckpoint Kinase 2Fanconi Anemia Complementation Group N ProteinFemaleGenes, BRCA2Germ-Line MutationHeterozygoteHumansWhiteAtaxia Telangiectasia Mutated ProteinsATM protein, humanBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCheckpoint Kinase 2CHEK2 protein, humanFanconi Anemia Complementation Group N ProteinPALB2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.